Optimizing MDR-TB clinical trials: Insights from the first global MDR-TB clinical trials landscape meeting

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S1-S3

  Robert Horsburgh, C ^a,b   Rusen, I D ^c   Mitnick, Carole D ^d,e  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Vital Strategies   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; LINEZOLID; PRETOMANID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); EDITORIAL; HUMAN; MORBIDITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA; UNITED STATES;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85031501754     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0568     Document Type: Editorial

References (26)

1. World Health Organization. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. Geneva, Switzerland: WHO, 2015.
2. Dheda K, Gumbo T, Gandhi N R, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2014; 2: 321-338.
3. Ahuja S D, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med 2012; 9: 1212.
4. Orenstein E W, Basu S, Shah N S, et al, Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
5. Cegielski J P, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-1063.
6. Cox H S, Sibilia C, Feuerriegel S, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359: 2398-2400.
7. Shin S S, Keshavjee S, Gelmanova I Y, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
8. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and procts for the future. J Infect Dis 2012; 205 (Suppl 2): S241-S249.
9. Dooley K E, Obuku E A, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-1358.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
12. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva, Switzerland: WHO, 2013.
13. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2014.23. Geneva, Switzerland: WHO, 2014.
14. Mitnick C D, Rusen I D, Bain L J, Horsburgh C R. Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting. BMC Proceedings 2015; 9 (Suppl 8): S1.
15. Davies G R, Phillips P P, Jaki T. Adaptive clinical trials in tuberculosis: applications, challenges and solutions. Int J Tuberc Lung Dis 2015; 19: 626-634.
16. Phillips P P J. Methodological considerations in clinical trials for new MDR-TB treatment regimens. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S4-S7.
17. Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick C D. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S8-S12.
18. Davies G R, Wallis R S. Methods for selecting regimen duration to prevent relapse in drug-susceptible and drug-resistant TB. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S13-S17.
19. Milstein M, Brzezinski A, Varaine F, Mitnick C D. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S18-S23.
20. Furin J, Alirol E, Allen E, et al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis 2016; 20: 290-294.
21. Dheda K, Limberis J, Esmail A, Maartens G. Selected questions and controversies about bedaquiline: a view from the field. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S24-S32.
22. Gupta R, Wells C D, Hittel N, Hafkin J, Geiter L J. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S33-S37.
23. Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S38-S41.
24. Sterling T R. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S42-S47.
25. Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S48-S51.
26. O'Donnell M R, Padayatchi N, Metcalfe J Z. Elucidating the role of clofazimine for the treatment of tuberculosis. Int J Tuberc Lung Dis 2016; 20 (Suppl 2): S52-S57.